Developed to target the hepatitis C virus to support clinical recovery and alleviate liver inflammation in patients across all major viral genotypes.
Mechanism of Action
This combination drug blocks two different proteins that the Hepatitis C virus needs to replicate. Sofosbuvir stops the virus from copying its genetic material, while Velpatasvir prevents the assembly of new virus particles, halting the infection.
Route of Administration
Oral
Onset Time
Steady state in 2–3 days
Duration
24 hours
Contraindications
Concurrent use with amiodarone, Hypersensitivity to components, Severe renal impairment
Severe Adverse Events
Severe bradycardia (with amiodarone), Hepatitis B virus reactivation, Liver failure, Severe allergic reactions
Common Side Effects
Fatigue, Headache, Mild nausea
Uncommon Side Effects
Insomnia, Weakness, Anemia
Drug Interactions
Amiodarone, Rifampin, Carbamazepine, St. John's Wort, Antacids, Digoxin
Pregnancy Safety Warnings
Use only if benefit outweighs potential risk; consult a specialist.
Age Restrictions
Approved for adults and children 3 years and older.
Information for Velpanat is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
